Rhode Island 2023 Regular Session

Rhode Island House Bill H5255 Compare Versions

Only one version of the bill is available at this time.
OldNewDifferences
11
22
33
44
55 2023 -- H 5255
66 ========
77 LC000787
88 ========
99 S TATE OF RHODE IS LAND
1010 IN GENERAL ASSEMBLY
1111 JANUARY SESSION, A.D. 2023
1212 ____________
1313
1414 A N A C T
1515 RELATING TO INSURANCE -- BENEFIT DETERMINATION AND UT ILIZATION
1616 REVIEW ACT
1717 Introduced By: Representatives Edwards, Ackerman, Kazarian, Alzate, Potter, Bennett,
1818 Caldwell, Craven, Casey, and Casimiro
1919 Date Introduced: January 27, 2023
2020 Referred To: House Health & Human Services
2121
2222
2323 It is enacted by the General Assembly as follows:
2424 SECTION 1. Chapter 27-18.9 of the General Laws entitled "Benefit Determination and 1
2525 Utilization Review Act" is hereby amended by adding thereto the following section: 2
2626 27-18.9-16. Utilization review decisions. 3
2727 (a) A utilization review decision shall not retrospectively deny coverage for health care 4
2828 services provided to a covered person when prior approval has been obtained from the insurer or 5
2929 its designee for those services, unless the approval was based upon fraudulent, materially 6
3030 inaccurate, or misrepresented information submitted by the covered person, authorized person, or 7
3131 the provider. 8
3232 (b) For health benefit plans issued or renewed on or after the effective date of this section, 9
3333 an insurer shall not require or conduct a prospective or concurrent review for a prescription 10
3434 medicine: 11
3535 (1) That is used in the treatment of alcohol or opioid use disorder; 12
3636 (2) That contains Methadone, Buprenorphine or Naltrexone; or 13
3737 (3) That was approved before the effective date of this section by the United States Food 14
3838 and Drug Administration for the mitigation of opioid withdrawal symptoms. 15
3939 (c) In conducting utilization reviews for Medicaid benefits, each Medicaid managed care 16
4040 organization shall use the medical necessity criteria selected by the Rhode Island division of 17
4141 insurance for making determinations of medical necessity and clinical appropriateness pursuant to 18
4242
4343
4444 LC000787 - Page 2 of 3
4545 the utilization review plan. 1
4646 SECTION 2. This act shall take effect upon passage. 2
4747 ========
4848 LC000787
4949 ========
5050
5151
5252 LC000787 - Page 3 of 3
5353 EXPLANATION
5454 BY THE LEGISLATIVE COUNCIL
5555 OF
5656 A N A C T
5757 RELATING TO INSURANCE -- BENEFIT DETERMINATION AND UTILIZATION
5858 REVIEW ACT
5959 ***
6060 This act would establish a prohibition on health care insurers from requiring or conducting 1
6161 a review for prescription medicine that is used in the treatment of alcohol or opioid use disorder, 2
6262 that contains Methadone, Burenorphine, or Naltrexone or that was approved for the mitigation of 3
6363 opioid withdrawal symptoms. 4
6464 This act would take effect upon passage. 5
6565 ========
6666 LC000787
6767 ========